Growth Metrics

Iovance Biotherapeutics (IOVA) EBIT Margin (2023 - 2025)

Historic EBIT Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to 140.69%.

  • Iovance Biotherapeutics' EBIT Margin rose 114200.0% to 140.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 166.31%, marking a year-over-year increase of 3069100.0%. This contributed to the annual value of 240.92% for FY2024, which is 384940700.0% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' EBIT Margin is 140.69%, which was up 114200.0% from 189.78% recorded in Q2 2025.
  • Iovance Biotherapeutics' EBIT Margin's 5-year high stood at 117.48% during Q4 2024, with a 5-year trough of 46254.62% in Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' EBIT Margin had a median value of 286.7% in 2024 and averaged 11428.64%.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 459269900bps in 2024, then surged by 114200bps in 2025.
  • Iovance Biotherapeutics' EBIT Margin (Quarter) stood at 25156.85% in 2023, then soared by 100bps to 117.48% in 2024, then fell by -20bps to 140.69% in 2025.
  • Its EBIT Margin stands at 140.69% for Q3 2025, versus 189.78% for Q2 2025 and 245.76% for Q1 2025.